聯系電話
- 聯系人:
- 楊經理
- 電話:
- 021-50724187 021-50724961
- 手機:
- 15921799099
- 傳真:
- 021-50724961
- 地址:
- 上海浦東川沙鎮川沙路6619號上海起發實驗試劑有限公司
- 個性化:
- www.qfbio.com
- 網址:
- www.qfbio.com
掃一掃訪問手機商鋪
世界*實驗材料供應商 BioCheck正式授權上海起發為其中國代理, BioCheck在一直是行業的*,一直為廣大科研客戶提供zui為的產品和服務,上海起發一直秉承為中國科研客戶帶來的產品,的服務,簽約 BioCheck就是為了給廣大科研客戶帶來更加完善的產品和服務,您的滿意將是我們zui大的收獲
BioCheck中國代理, BioCheck上海代理, BioCheck北京代理,BioCheck廣東代理, BioCheck江蘇代理BioCheck湖北代理,BioCheck天津,BioCheck黑龍江代理,BioCheck內蒙古代理,BioCheck吉林代理,BioCheck福建代理, BioCheck江蘇代理, BioCheck浙江代理, BioCheck四川代理
BIOCHECK公司由創始人 Dr. John Chen, Medix創立, 是一家抓也提供腫瘤標志物,心肌標志物,激素類zui高性價比的抗體的公司。
簡要原理
利用競爭酶聯免疫方法,預先在微孔中包被羊抗兔抗體,實驗時先后加入氯霉素標準品或待測樣本,氯霉素酶標抗原和兔抗氯霉素抗體。經過室溫溫育,反應液中的兔抗氯霉素抗體與微孔板上的羊抗兔抗體結合,待測樣品中的抗原與氯霉素酶標抗原競爭微孔板上的兔抗氯霉素抗體。洗滌后,沒有與抗
體結合的待測樣品中的抗原或酶標抗原被洗去,再加入反應底物,結合的酶標抗原的酶將底物轉化為藍色產物,加入終止液后顏色由藍色變為黃色。反應完成后,樣品中氯霉素含量越多,反應呈色就越淺;反之,樣品中氯霉素含量越少,則呈色越深。利用標準曲線可計算出樣品中氯霉素含量。
技術參數
檢測蜂蜜、蛋類、牛奶、奶粉、水產品、動物組織(肌肉、肝臟等)、飼料、血清、血漿及尿液樣本中存在的氯霉素,定量限可達0.025 ppb。
No. | 樣品 | 檢測下限 |
1 | 蜂蜜 | 0.02 ppb (0.02 ng/g) |
2 | 蛋類 | 0.02 ppb (0.02 ng/g) |
3 | 牛奶 | 0.002 ppb (0.002 ng/ml) |
4 | 奶粉 | 0.012 ppb (0.012 ng/g) |
5 | 蝦,魚及肉類 | 0.08 ppb (0.08 ng/g) |
6 | 飼料 | 0.08 ppb (0.08 ng/g) |
7 | 血清/血漿 | 0.02 ppb (0.02 ng/ml) |
8 | 尿液 | 0.04 ppb (0.04 ng/ml) |
交叉反應
名稱 | 百分比 |
氯霉素堿 | 0.4% |
甲基氯霉素 | <0.04% |
回收率
No. | 樣品 | 回收率 |
1 | 蜂蜜 | 70% ~ 110% |
2 | 牛奶 | 90% ~ 130% |
3 | 蛋,蝦,魚及肉類 | 95% ~ 120% |
4 | 飼料 | 95% ~ 120% |
5 | 血清 / 血漿 | 90% ~ 120% |
6 | 尿液 | 100% ~ 130% |
PD-L1 ENZYME IMMUNOASSAY TEST KIT
Catalog Number: BC-1303
Enzyme Immunoassay for the Quantitative Determination of PD-L1 Concentration in Human Serum and Plasma
FOR RESEARCH USE ONLY
Not for use in diagnostic procedures
INTRODUCTION
Programmed death receptor-ligand 1 (PD-L1, B7- H1, CD274) is a biomarker from the B7 family that is expressed on a variety of cells and upregulated in response to pro-inflammatory cytokines such as interferon gamma1,2,3. PD-L1 interacts with PD-1, a co-receptor expressed by exhausted T cells, to encourage an immunosuppressive tumor microenvironment by decreasing T cell receptor mediated proliferation and cytokine production4, 5. The PD-1/PD-L1 interaction functions as an immune checkpoint in a process known as immunoediting where the host immune system eliminates highly immunogenic tumors while allowing less immunogenic tumor to evade it2, 6. Multiple solid tumor types including melanoma, renal cell carcinoma, non-small cell lung cancer, ovarian, and colorectal cancer utilize this PD-1/PD -L1 immunoediting mechanism2. Current treatment has focused on blocking the PD-1/PD-L1 interaction to reduce tumor evasion by inhibiting PD-1, with new focus on PD-L1 as well1, 2.
PRINCIPLE OF THE ASSAY
The PD-L1 ELISA is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay system utilizes a unique monoclonal antibody pair directed against a distinct antigenic determinant on the PD-L1 molecule. One mouse monoclonal anti- PD- L1 antibody is used for solid phase immobilization (on the microtiter wells). Another mouse monoclonal anti-PD-L1 antibody conjugated to horseradish peroxidase (HRP) is in the enzyme conjugate solution. The test samples are allowed to react sequentially with the two antibodies, resulting in the PD-L1 molecules to be sandwiched between the solid phase and enzyme-linked antibodies. After two separate 60- minute incubation steps at room temperature, the wells are rinsed with Wash Buffer to remove unbound labeled antibodies. TMB Reagent is added and incubated for 30 minutes under dark conditions, resulting in the development of a blue color. The color development is stopped with the addition of Stop Solution, changing the color to yellow. The concentration of
PD-L1 is directly proportional to the color intensity of the test samples. Absorbance is measured spectrophotometrically at 450 nm.
REAGENTS AND MATERIALS PROVIDED
- Antibody-Coated Wells (1 plate, 96 wells)
Microtiter wells coated with mouse monoclonal anti-PD-L1
- 20 ng/ml PD-L1 Standard (0.5 mL /vial)
20 ng/mL PD-L1 in phosphate buffer-BSA solution with preservatives
3. Standard and Sample Diluent (30 mL/bottle, 1 bottle)
Contains phosphate buffer-BSA solution with preservatives
- Enzyme Conjugate Reagent (12 mL/vial, 1 vial)
Contains mouse monoclonal anti-PD-L1 conjugated to horseradish peroxidase
- 20X Wash Buffer (50 mL/bottle, 1 bottle) Phosphate buffer with detergents
- TMB Reagent (11 mL/bottle, 1 bottle)
Contains one-step TMB solution
- Stop Solution (11 mL/bottle, 1 bottle)
Contains diluted hydrochloric acid (1N HCl)
STORAGE CONDITIONS
- Store the unopened kit at 2-8°C upon receipt and when it is not in use, until the expiration shown on the kit label. Refer to the package label for the expiration date.
- Keep microtiter plate in a sealed bag with desiccant to minimize exposure to damp air.
REAGENT PREPARATION
- All reagents should be allowed to reach room temperature (18-25°C) before use.
- For each test run, prepare a fresh standard set.
- Dilute 20 ng/mL standard to 5 ng/mL. Prepare two-fold serial dilutions of the 5 ng/mL Standard with Standard/Sample Diluent:
- 5 ng/mL: 0.15 mL of 20 ng/mL+ 0.45 mL of Standard/Sample Diluent
- 2.5 ng/mL: 0.25 mL of 5 ng/mL+ 0.25 mL of Standard /Sample Diluent
- 1.25 ng/mL: 0.25 mL of 2.5 ng/ml + 0.25 mL of Standard/Sample Diluent
- 0.625 ng/mL: 0.25 mL of 1.25 ng/mL + 0.25 mL of Standard/Sample Diluent
- 0.313 ng/mL: 0.25 mL of 0.625 ng/mL + 0.25 mL of Standard/Sample Diluent
- 0.156 ng/mL: 0.25 mL of 0.313 ng/mL + 0.25 mL of Standard Diluent
- 0.078 ng/mL: 0.25 mL of 0.156 ng/mL + 0.25 mL of Standard Diluent
- 0 ng/mL: 0.25 mL of Standard Diluent
- Patient samples need to be diluted 4-fold prior to use. Prepare a series of small tubes (i.e., 1.5 mL microcentrifuge tubes) and mix 60 µL of serum with 180 µLStandard/Sample Diluent.
- Working Wash Buffer: Preparation of 1X Wash Buffer from 20X Stock. Add 50 mL of 20X Wash Buffer Stock to 950 mL of DI H2O. The Working Wash Buffer is stable at 2-8°C for 30 days. NOTE: Any crystals that may be present due to high salt concentration must be redissolved at room temperature before making the dilution.
ASSAY PROCEDURE
- Prepare Standards. See Reagent Preparation.
- Dilute samples 1:4 dilution. See Reagent Preparation.
- Secure the desired number of coated wells in the holder.
- Dispense 100 m L of PD-L1 standards, and DILUTED specimens into the appropriate wells.
- Incubate for 60 minutes at room temperature (18-25 °C).
- Remove incubation mixture by flicking plate contents into a waste container. Rinse and flick the microtiter wells 5 times with 300 m L Working Wash Buffer. Strike the wells onto absorbent paper or paper towels to remove all residual water droplets.
- Dispense 100 m L of PD-L1 Working Enzyme Conjugate Reagent into each well.
- Incubate for 60 minutes at room temperature (18-25 °C).
- Remove incubation mixture by flicking plate contents into a waste container. Rinse and flick the microtiter wells 5 times with 300 uL Working Wash Buffer. Strike the wells onto absorbent paper or paper towels to remove all residual water droplets.
- Dispense 100 mL TMB solution into each well.
- Incubate for 30 minutes at room temperature (18-25 °C).
- Stop the reaction by adding 100 mL of Stop Solution into each well.
- Gently mix for 30 seconds. It is important to make sure that all the blue color changes to yellow color compley.
- Read absorbance at 450 nm with a microtiter well reader within 15 minutes.
CALCULATION OF RESULTS
- Calculate the mean absorbance value (OD450) for each set of reference standards, controls and samples.
- Construct a standard curve by plotting the mean absorbance obtained for each reference standard against its concentration in ng/ml on graph paper, with absorbance on the vertical (y) axis and concentration on the horizontal (x) axis.
- The corresponding concentration of PD-L1 (ng/mL) can be determined from the standard curve using the mean absorbance value for each sample. Depending on experience and/or the availability of computer capability, other methods of data reduction may be employed.
- The obtained values of the samples should be multiplied by the dilution factor of 4 to obtain PD-L1 results in ng/ml.
EXAMPLE OF STANDARD CURVE
Results of a typical standard run with absorbency readings at 450 nm shown on the Y axis against PD-L1 concentrations shown on the X axis. NOTE: This standard curve is for the purpose of illustration only, and should not be used to calculate unknowns. Each laboratory must generate its own data and standard curve in each experiment.
PD-L1 | Absorbance |
(ng/ml) | (450 nm) |
0 | 0.042 |
0.078 | 0.141 |
0.156 | 0.236 |
0.313 | 0.415 |
0.625 | 0.726 |
1.25 | 1.283 |
2.5 | 2.100 |
5 | 3.053 |
nm | 3.5 |
|
|
|
|
|
3 |
|
|
|
|
| |
(450 |
|
|
|
|
| |
2.5 |
|
|
|
|
| |
2 |
|
|
|
|
| |
Absorbance |
|
|
|
|
| |
1.5 |
|
|
|
|
| |
1 |
|
|
|
|
| |
0.5 |
|
|
|
|
| |
0 |
|
|
|
|
| |
| 0 | 1 | 2 | 3 | 4 | 5 |
|
|
| PD-L1 Conc. (ng/ml) |
|
PERFORMANCE CHARACTERISTICS
- Sensitivity
The minimum detectable concentration of the PD-L1 ELISA assay as measured by 2SD from the mean of a zero standard is estimated to be 0.02 ng/ml.
- Precision
- Intra-Assay Precision
Within-run precision was determined by replicate determinations of three different samples in one assay. Within-assay variability is shown below:
Sample | 1 | 2 | 3 |
# Replicates | 24 | 24 | 24 |
Mean PD-L1 (ng/mL) | 1.5 | 3.0 | 7.4 |
S.D. | 0.04 | 0.05 | 0.18 |
C.V. (%) | 2.4% | 1.6% | 2.4% |
2
- Inter-Assay Precision
Between-run precision was determined by replicate measurements of three different samples over a series of individually calibrated assays. Between-assay variability is shown below:
Sample | 1 | 2 | 3 |
# Replicates | 20 | 20 | 20 |
Mean PD-L1 (ng/mL) | 1.6 | 3.0 | 7.4 |
S.D. | 0.04 | 0.12 | 0.26 |
C.V. (%) | 2.5% | 4.1% | 3.5% |
- Recovery and Linearity Studies
- Recovery
Samples were spiked with known PD-L1 levels and assayed in duplicate. The mean recovery was 90%.
Sample | EXPECTED | OBSERVED | % RECOVERY |
| [PD-L1] | [PD-L1] |
|
| (ng/mL) | (ng/mL) |
|
1 | 2 | 1.8 | 90% |
2 | 5 | 4.6 | 92% |
3 | 10 | 8.9 | 89% |
- Linearity
Three samples were serially diluted to determine linearity. The mean recovery was 110.3%.
# | Dilution | Expected | Observed |
|
|
| Conc. (ng/ml) | Conc. (ng/ml) | % Expected |
1. | 1:4 | 1.6 | 1.6 | N/A |
| 1:8 |
| 1.7 | 106.3% |
| 1:16 |
| 1.7 | 106.3% |
| 1:32 |
| 1.8 | 112.5% |
|
|
|
| Mean = 108.4% |
2. | 1:4 | 3.7 | 3.7 | N/A |
| 1:8 |
| 4.0 | 108.1% |
| 1:16 |
| 4.0 | 108.1% |
| 1:32 |
| 4.1 | 110.8% |
|
|
|
| Mean = 109.0% |
|
|
|
|
|
3. | 1:4 | 7.4 | 7.4 | N/A |
| 1:8 |
| 8.3 | 112.2% |
| 1:16 |
| 8.6 | 116.2% |
| 1:32 |
| 8.3 | 112.2% |
Mean = 113.5%
REFERENCES
- Herbst, Roy S., et al. "Predictive correlates of response to the
anti-PD-L1 antibody MPDL3280A in cancer
patients." Nature 515.7528 (2014): 563.
- Pa, Sandip Pravin, and Razelle Kurzrock. "PD-L1 expression as a predictive biomarker in cancer immunotherapy." Molecular cancer therapeutics 14.4 (2015): 847-856.
- Topalian, Suzanne L., Charles G. Drake, and Drew M. Pardoll. "Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity." Current opinion in immunology 24.2 (2012): 207-212.
- Blank, Christian, and Andreas Mackensen. "Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion." Cancer immunology, immunotherapy 56.5 (2007): 739-745.
- Barber, Daniel L., et al. "Restoring function in exhausted CD8 T cells during chronic viral infection." Nature 439.7077 (2006): 682.
- Teng, Michele WL, et al. "Classifying cancers based on T-cell infiltration and PD-L1." Cancer research 75.11 (2015): 2139-2145.
部分產品如下:
貨號 | 品名 | Tests/Kit | 規格 | 品牌 |
70748 | Mouse Monoclonal anti-human PD-1 (Capture) | Purified | 0.1/0.5/1 mg | BioCheck |
70749 | Mouse Monoclonal anti-human PD-1 (Capture) | Purified | 0.1/0.5/1 mg | BioCheck |
70750 | Mouse Monoclonal anti-human PD-1 (Detection) | Purified | 0.1/0.5/1 mg | BioCheck |
70751 | Mouse Monoclonal anti-human PD-L1 (Capture) | Purified | 0.1/0.5/1 mg | BioCheck |
70752 | Mouse Monoclonal anti-human PD-L1 (Capture) | Purified | 0.1/0.5/1 mg | BioCheck |
70753 | Mouse Monoclonal anti-human PD-L1 (Detection) | Purified | 0.1/0.5/1 mg | BioCheck |
70745 | Mouse monoclonal anti-human Lp-PLA2 (Capture) | Purified | 0.5 mg | BioCheck |
70746 | Mouse monoclonal anti-human Lp-PLA2 (Detection) | Purified | 0.5 mg | BioCheck |
70747 | Mouse monoclonal anti-human Lp-PLA2 (Detection) | Purified | 0.5 mg | BioCheck |
我們公司zui大優勢是強大的采購,
1:基本什么都能進口,血清,抗體,耗材,還有部分限制進口的,
2:貨品全,現經營過700多個品牌,基本所有生物試劑耗材都可以進口,特別是冷偏的產品那就更有優勢,
3:提供加急服務,一般1-2周到貨,超過時限加急費全免
4:價格公道,絕大部分價格有優勢,當然不能保證100%產品都是,因為意味著沒有服務.
5:良好的信譽,大部分客戶我們提供貨到付款服務,客戶包括清華,北大 交大 復旦,中山等100多所大學,ROCHE,阿斯利康,國藥 ,fisher等500多家公司
6:我們*代理的品牌有:Antibody Research Corporation,arcticzymes,Biorelevant,AmberGen, Inc. ,clemente-associates,clodronaiposomes,Columbia Biosciences,enzyme research,Gene Bridges GmbH,Genovis,AmberGen, Inc. Biotechnology GmbH,Haematologic Technologies HTI Haemtech,hookelabs,Immudex,Innovative Research of America,inspiralis ,List Biological Laboratories, Inc.,lumafluor,Microsurfaces,multiplicom,nanotools,Pel-Freez Biologicals,pentapharm,progen,Protein Ark,QA-Bio,Inc,QA-Bio,IncQuickZyme Biosciences,Teknova,TriLink BioTechnologies, Inc.,Zyagen Laboratories 等
7:我們還是invitrogen,qiagen,Midland BioProducts Corporationam,sigma;neb,roche,merck, rnd,BD, GE,pierce,BioLegend等知名*批發,歡迎合作。